Wednesday, July 8, 2026

pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN

SUPERNUS PHARMACEUTICALS

SUPERNUS PHARMACEUTICALS is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker SUPN. Primary therapeutic focus areas include Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), P

9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
Status
Public
HQ
9715 Key West Ave, Rockville, Maryland 20850, US
Founded
2005
Employees
828
Programs
55
Drugs
25
Patents
68
Clinical program

Brexanolone

Phase 3 · small molecule · Post Partum Depression

Brexanolone for Post Partum Depression is a Phase 3 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

← All SUPERNUS PHARMACEUTICALS, INC. projects Phase 3 small molecule completed

Internal code 547-PPD-304

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
SUPERNUS PHARMACEUTICALS, INC.
Phase
Phase 3
Modality
small_molecule
Indication
Post Partum Depression
Status
completed
Trials
1

Clinical trials